secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K/A
Filed at:   2025-06-27T23:59:59+00:00
Accession:  0001171843-25-004196
Event type: regulatory
Sentiment:  negative
Materiality: 0.55
Item codes: 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience misses audit committee independence; Nasdaq confirms; cure period through June 2026
--------------------------------------------------------------------------------

- Alan Edrick resigned from Board and Audit Committee effective June 10, 2025, leaving only two audit committee members.
- Nasdaq Staff notified Company on June 26, 2025 that it no longer meets Audit Committee Composition Requirement (Rule 5605(c)(2)(A)).
- Company has cure period until earlier of next annual meeting or June 10, 2026 to fill vacancy with independent director.
- Company intends to appoint a new independent Board member expeditiously to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325004196/0001171843-25-004196-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184325004196/f8ka_062725.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004196

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer